Is Utah Medical Products, Inc. (UTMD) Overvalued?
We dive into why Utah Medical Products, Inc. (UTMD) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Tudor Pop
| Share Statistics | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $198.0 | $363.7 | 29% |
|
| Shares Out (Mil) | 3.2 | 41.1 | 11% |
|
| Institutional Ownership | 90.7% | 82.7% | 58% |
|
| Float (Mil) | 2.5 | 36.7 | 7% |
|
| Beta | 0.41 | 0.89 | 22% |
|
| Avg Daily Volume (000s) | 22 | 326 | 22% |
|
| Price Change (52-week) |
28.9% | 54.6% | 79% |
|
| Growth | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (1.8%) | 11.8% | 14% |
|
| Net Income (5yr) | 0.9% | (5.8%) | 41% |
|
| EPS (5yr) | 3.4% | 10.6% | 36 |
|
| Dividends (5yr) | 1.8% | 0.0% | 83% |
|
| Cash Flow (5yr) | (18.6%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $123 | 17% |
|
| Net Income (TTM) (Mil) | $11 | ($9) | 45% |
|
| EPS (TTM) | $3.340 | ($0.300) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $12 | ($1) | 38% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $21 | 12% |
|
| Enterprise Value (Q1) (Mil) | $120 | $381 | 24% |
|
| Valuation | UTMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.79 | 2.41 | 54% |
|
| P/E | 20.8 | 25.5 | 59% |
|
| Dividend Yield | 1.8% | 0.0% | 73% |
|
| PEG (5yr hist) | 6.1 | 1.3 | 91% |
|
| Ratios | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.7% | 59.5% | 71% |
|
| Net Margin | 30.5% | (5.0%) | 89% |
|
| ROA | 8.5% | (10.4%) | 83% |
|
| ROE | 8.8% | (8.4%) | 52% |
|
| Liabilities to Assets | 4.1% | 45.8% | 2% |
|
| F-Score | 5 | 4 | 50% |
|
Passing Stock Screens
As of 11/20/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 6.4% |
| +/- S&P 500: | -1.0 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors